Clinical Trials Sponsored by Ali Rezai

Total 4705 results

Eli Lilly and Company

Completed

A Study of LY3361237 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Breast Cancer

United States, Canada
Eli Lilly and Company

Completed

A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States, Spain, France, Italy, United Kingdom
Eli Lilly and Company

Completed

A Study of Dulaglutide in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2216684 and Theophylline in Healthy Subjects

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study of LY3031207 in Healthy Subjects

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Safety Study of LY3372689 Given By Mouth to Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY2216684 in Healthy Participants

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread

Solid Tumor | Malignant Solid Tumor | Metastatic Tumor

Germany, United States, France
Eli Lilly and Company

Completed

A Study of LY2495655 in Healthy Subjects

Healthy Volunteer

United States
Eli Lilly and Company

Completed

A Bioavailability Study of LY2452473 and Tadalafil

Erectile Dysfunction

United States
Eli Lilly and Company

Completed

A Phase 1 Study of LY2874455 in Participants With Advanced Cancer

Advanced Cancer

Australia, Korea, Republic of
Eli Lilly and Company

Completed

A Study of LY2922470 in Healthy Participants and Participants With Diabetes

Diabetes Mellitus, Type 2

Singapore
Eli Lilly and Company

Completed

Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance

Chronic Kidney Disease

Netherlands
Eli Lilly and Company

Terminated

A Study for Patients With Acute Leukemia

Acute Leukemia

United States
Eli Lilly and Company

Completed

A Study of LY3090106 in Japanese and Caucasian Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

Biomarker Study in Participants With Migraine

Migraine Disorders

United States
Eli Lilly and Company

Completed

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

Prostate Cancer

Spain, Poland, Germany, United States
Eli Lilly and Company

Completed

A Study of LY2484595 on Pharmacokinetics in Healthy Participants

Healthy Participants

United States
Eli Lilly and Company

Completed

A Study of LY3113593 in Participants With Chronic Kidney Disease

Chronic Kidney Disease

United States
Eli Lilly and Company

Completed

A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY3015014 in Healthy Participants With High Cholesterol

Hypercholesterolemia | Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Phase 1 Study in Patients With Solid Tumors

Solid Tumors

United States
Eli Lilly and Company

Completed

A Study of Galcanezumab in Healthy Participants.

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3143753 and LY3185643 in Healthy Participants

Healthy

United Kingdom
Eli Lilly and Company

Completed

A Study of Ixekizumab in Participants With Plaque Psoriasis

Psoriasis

United States
Eli Lilly and Company

Completed

A Study of the Effect of LY2216684 on Lorazepam

Major Depressive Disorder

United Kingdom
Eli Lilly and Company

Completed

An Interaction Study of LY3200882 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue

Diabetes Mellitus, Type 1

Austria
Eli Lilly and Company

Completed

A Study of Japanese Rheumatoid Arthritis Participants

Rheumatoid Arthritis

Japan
Eli Lilly and Company

Completed

A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

Type 1 Diabetes Mellitus

United States
Eli Lilly and Company

Completed

A Study of Galcanezumab in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Advanced Cancer

United States
Eli Lilly and Company

Completed

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Head and Neck Neoplasms

United States, France
Eli Lilly and Company

Completed

A Study of IMC-RON8 in Advanced Solid Tumors

Cancer

United States
Eli Lilly and Company

Completed

A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Poland
Eli Lilly and Company

Terminated

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Renal Cell Carcinoma | Metastases, Neoplasm | Neuroendocrine Tumors | Carcinoma, Non-small Cell Lung

France, United States
Eli Lilly and Company

Completed

A Study of LY3025876 in Participants With Diabetes

Type 2 Diabetes Mellitus

United States
Eli Lilly and Company

Completed

A Study of LY2216684 and Warfarin in Healthy Subjects

Major Depressive Disorder

United States
Eli Lilly and Company

Terminated

A Safety Study in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States
Eli Lilly and Company

Completed

Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Essential Thrombocythemia

United States
Eli Lilly and Company

Completed

C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors

Advanced Cancer

Switzerland
Eli Lilly and Company

Completed

A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors

Solid Tumors

United States
Eli Lilly and Company

Completed

A Multiple Dose Study of LY3023703 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Colorectal Cancer | Metastatic Cancer | Non-small Cell Lung Cancer | Advanced Cancer

United States, Germany
Eli Lilly and Company

Completed

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

Arthritis, Rheumatoid

United States, Argentina, Germany, Puerto Rico, Mexico, Belgium, Poland, Brazil, Austria, Canada
Eli Lilly and Company

Completed

Study of LY3154207 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis

Hungary, United States, France, Ukraine, Poland, Germany, Israel, Russian Federation, Czechia, Serbia, Romania, Slovakia, Bulgaria

Clinical Trials Sponsored by Ali Rezai

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations